Xenetic Biosciences
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Xenetic Biosciences generated cash of -$4,114,219, which is more than the previous year. Cash used in financing activities reached the amount of $0 last year. Net change in cash is therefore -$4,114,219.
Cash Flow
| 2014 | -12.32M | -52.18K | 9.81M |
|---|---|---|---|
| 2015 | -5.30M | 6.21K | 3M |
| 2016 | -8.78M | -16.79K | 12.71M |
| 2017 | 1.49M | -9.26K | 125 |
| 2018 | -6.46M | 22.5K | 1.48M |
| 2019 | -6.39M | 2K | 16.12M |
| 2020 | -4.26M | 0 | 5.42M |
| 2021 | -4.73M | 0 | 11.45M |
| 2022 | -4.64M | -500K | 0 |
| 2023 | -4.11M | 0 | 0 |
XBIOW Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 13.09M | 18.24M | 11.52M | 10.36M | 638.11K | 5.59M | 4.04M | 132.22K | 2.50M | 4.83M |
Operating activities | ||||||||||
Net income | -4.13M | -6.55M | -5.64M | -10.89M | -12.77M | -7.30M | -3.59M | -54.20M | -12.50M | -14.30M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 0 | 27.04K | 35.48K | 28.83K | 27.48K | 15.82K | 23.78K | 36.44K | 56.11K | 88.68K |
Stock-based compensation expense | 283.08K | 511.48K | 410.43K | 468.91K | 853.51K | 1.42M | 1.91M | 2.10M | 2.74M | 1.51M |
| Deferred income tax benefit | 283.08K | 511.48K | 410.43K | 468.91K | 853.51K | 1.42M | 1.91M | 2.10M | 2.74M | 1.51M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 3M | -3M | 0 | -24.46K |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 8.18K | -243.66K | 0 | 0 |
Accounts payable | -263.57K | -347.94K | 457.13K | -378.11K | -227.96K | -343.87K | -8.18K | 243.66K | 943.90K | -479.01K |
Cash generated by operating activities | -4.11M | -4.64M | -4.73M | -4.26M | -6.39M | -6.46M | 1.49M | -8.78M | -5.30M | -12.32M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | -500K | 0 | 0 | 0 | 0 | -9.26K | -16.79K | -1.66K | -57.66K |
Acquisitions Net | 0 | -500K | 0 | 0 | 2K | 22.5K | 0 | 0 | 7.88K | 43.50K |
Cash generated by investing activities | 0 | -500K | 0 | 0 | 2K | 22.5K | -9.26K | -16.79K | 6.21K | -52.18K |
Financing activities | ||||||||||
Common Stock Issued | 16 | 0 | 11.45M | 5.42M | 16.12M | 1.48M | 125 | 0 | 3.74M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 1.29M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3M | 0 |
Cash used in financing activities | 0 | 0 | 11.45M | 5.42M | 16.12M | 1.48M | 125 | 12.71M | 3M | 9.81M |
Net Change In Cash | -4.11M | -5.14M | 6.71M | 1.15M | 9.72M | -4.96M | 1.48M | 3.91M | -2.37M | -2.33M |
Cash at end of period | 8.98M | 13.09M | 18.24M | 11.52M | 10.36M | 638.11K | 5.53M | 4.04M | 132.22K | 2.50M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |